S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CNTB

Connect Biopharma (CNTB) Stock Price, News & Analysis

$1.74
+0.13 (+8.07%)
(As of 03/28/2024 ET)
Today's Range
$1.67
$1.97
50-Day Range
$1.05
$1.61
52-Week Range
$0.53
$2.84
Volume
470,054 shs
Average Volume
131,281 shs
Market Capitalization
$95.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Connect Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
244.8% Upside
$6.00 Price Target
Short Interest
Healthy
0.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Connect Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.76) to $0.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.74 out of 5 stars

Medical Sector

402nd out of 938 stocks

Pharmaceutical Preparations Industry

184th out of 423 stocks

CNTB stock logo

About Connect Biopharma Stock (NASDAQ:CNTB)

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.

CNTB Stock Price History

CNTB Stock News Headlines

Connect Biopharma (NASDAQ:CNTB) Trading Up 21.1%
AI healthcare stock poised for 36,996% growth?
Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...
AI healthcare stock poised for 36,996% growth?
Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...
CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd ADR CNTB
See More Headlines
Receive CNTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
4/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNTB
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$7.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+244.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.86 per share

Miscellaneous

Free Float
42,626,000
Market Cap
$95.82 million
Optionable
Optionable
Beta
-0.73
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Wubin Pan M.B.A. (Age 59)
    Ph.D., Co-Founder, President & Chairman of the Board of Directors
  • Dr. Zheng Wei Ph.D. (Age 60)
    Co-Founder, CEO & Director
  • Mr. Steven Chan (Age 52)
    Chief Financial Officer
  • Mr. Jiang Bian J.D.
    General Counsel & Chief Compliance Officer
  • Dr. Lei Sun Ph.D. (Age 60)
    VP of Biologics & Head of CMC
  • Dr. Raul Collazo Ph.D.
    VP & Global Head of Medical Affairs
  • Dr. Malinda V. Longphre Ph.D.
    VP & Head of US Clinical Operations

CNTB Stock Analysis - Frequently Asked Questions

Should I buy or sell Connect Biopharma stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Connect Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CNTB shares.
View CNTB analyst ratings
or view top-rated stocks.

What is Connect Biopharma's stock price target for 2024?

3 analysts have issued 1 year target prices for Connect Biopharma's stock. Their CNTB share price targets range from $5.00 to $7.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 244.8% from the stock's current price.
View analysts price targets for CNTB
or view top-rated stocks among Wall Street analysts.

How have CNTB shares performed in 2024?

Connect Biopharma's stock was trading at $1.18 on January 1st, 2024. Since then, CNTB shares have increased by 47.5% and is now trading at $1.74.
View the best growth stocks for 2024 here
.

Are investors shorting Connect Biopharma?

Connect Biopharma saw a drop in short interest in March. As of March 15th, there was short interest totaling 107,400 shares, a drop of 13.2% from the February 29th total of 123,700 shares. Based on an average daily volume of 133,300 shares, the short-interest ratio is currently 0.8 days. Currently, 0.2% of the shares of the company are sold short.
View Connect Biopharma's Short Interest
.

When is Connect Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 9th 2024.
View our CNTB earnings forecast
.

When did Connect Biopharma IPO?

Connect Biopharma (CNTB) raised $150 million in an IPO on Friday, March 19th 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO.

Who are Connect Biopharma's major shareholders?

Connect Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BML Capital Management LLC (3.74%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Connect Biopharma?

Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners